On the basis of geography, the global advanced medicinal therapy products are segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global advanced medicinal therapy products market, owing to the development in the field of cell and gene therapy. For instance, the innovative gene therapy known as CAR-T or chimeric antigen receptor T-cell therapy harnesses the body’s own immune cells to recognize and attack malignant cells. The T-cells are harvested and modified with a new gene. The new gene contains a protein that directs the T-cells to target and kill leukemia cells that have a specific antigen on the surface. Moreover, Food and Drug Administration (FDA) approved first gene therapy in the U.S. in 2017, leading a new approach to the treatment of cancer and other serious and life-threatening diseases. Moreover, Kymriah a cell based gene therapy has also been approved by FDA in 2017 in the U.S. for the treatment of patients with a form of acute lymphoblastic leukemia. Europe is also showcasing lucrative growth in advanced medicines therapy market, owing to new product approval in the region. For instance, in June 2019, bluebird bio has received marketing authorization from European Commission for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years and older with Transfusion-Dependent β-Thalassemia. ZYNTEGLO is the first gene therapy product approved for transfusion-dependent β-thalassemia. Furthermore, Asia Pacific is expected to be the fastest growing region for the global advanced therapy medicinal products market mainly due to rising number of skin burns cases and cancer diseases.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients